ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PXSL Pharmaxis Limited - Sponsored Adr (Australia) (MM)

28.6001
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Pharmaxis Limited - Sponsored Adr (Australia) (MM) PXSL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 28.6001 20:00:00
Open Price Low Price High Price Close Price Prev Close
28.6001 28.6001
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 28.6001 USD

Pharmaxis Limited - Sponsored Adr (Australia) (MM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.28B - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pharmaxis Limited - Sponsored Adr (Australia) (MM) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PXSL Message Board. Create One! See More Posts on PXSL Message Board See More Message Board Posts

Historical PXSL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Pharmaxis Limited - Sponsored Adr (Australia) (MM) Description

Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments of the group are Bronchitol and Aridol business; and New drug development. It generates a majority of the revenue from the Bronchitol and Aridol business which covers the intended clinical development, manufacture and sale of the Bronchitol and Aridol globally.

Your Recent History

Delayed Upgrade Clock